Skip to main content

Contested Capital

From the series Industry and pharmaceuticals

On August 15th, the White House published a long list of the most recent investments in American manufacturing. The statement emphasised the role of President Donald Trump who, with the aim of revitalising American industry [...], has spurred trillions of dollars of investments in US manufacturing, production, and innovation [The White House, “Trump Effect: A Running List of New US Investment in President Trump’s Second Term”].

The list includes around twenty pharmaceutical companies, which have announced a total commitment of over $340 billion in investments, more than half from European companies. Stephen Farrelly, an analyst at ING, estimates that investments in the United States announced by pharmaceutical multinationals amount to more than $400 billion [Il Sole 24 Ore, October 15th].

Political pressures and old problems

This is a response to the tariffs imposed by the Trump administration, and to the promise of exemption in exchange for the transfer of production activities to the US. In many cases, the mere threat was enough. The companies announced their investment plans before the US-EU agreement, which formalised a maximum tariff of 15% on the most expensive, branded medicines. The multibillion-dollar investments will be used to build new production facilities and research and development (R&D) centres in the United States, as well as to expand existing ones. The timeline for the projects is generally four-five years, in some cases extending up to ten. On the other hand, according to industry analysts, the construction and certification of a new production facility can take up to five years, without taking into account potential shortages of skilled labour [Reuters, September 26th]. The Big Pharma companies have indicated their willingness to respond to political pressures, notes the German newspaper Handelsblatt. This consideration also applies to American multinationals that have moved production abroad.

For European companies, the flow of capital is also responding to the pre-existing difficulties of the Union’s biopharmaceutical sector. Vas Narasimhan and Paul Hudson, CEOs of Novartis and Sanofi respectively, in a letter to the Financial Times on April 23rd, highlighted the decline in competitiveness of the European pharmaceutical industry. The uncertainty of tariffs is further reducing incentives to invest in the EU, where innovation is not valued, unlike in the United States and China. The US pharmaceutical market is twice the size of Europe’s, despite a smaller population [Letter: Brussels Must Get the Incentives Right for Pharma Investment”, Financial Times, April 23rd, 2025]. For European Life Sciences companies, Novartis and Sanofi believe, it is becoming more advantageous to invest in the US or China than in Europe.

The protectionist policy of the Trump administration on pharmaceutical products has therefore accelerated a flow of investment towards the US that was already underway. These are investments that the industry would have made anyway, is the view of the portfolio manager of an investment bank [Handelsblatt, October 1st].

The European pharmaceutical industry depends on the US market for 40-50% of its sales [Financial Times, April 24th]. The largest European companies have been present in the United States with production or R&D sites for decades, attracted not only by the size and profitability of a market where prices are much higher, but also by its scientific and technological strength. In his Report, Mario Draghi emphasised that in the US, innovation hubs that combine industry, universities, and investors have a critical mass that cannot be achieved in Europe. Meanwhile, the innovative capacity of Chinese biotechnology clusters is growing rapidly [The Future of European Competitiveness”, September 2024].

“Unexpected” effects

On September 25th, with a notice published in the Federal Register, the Trump administration announced the implementation of the framework agreement reached with the EU in July. A 15% tariff on a range of goods was formalised and exemptions were specified for hundreds of products. For medicines, the new tariff will be applied to branded drugs (patent-protected), but not to generic drugs and their chemical precursors, non-patented articles for use in pharmaceutical applications [Federal Register, “Implementing Certain Tariff-Related Elements of the US-EU Framework on an Agreement on Reciprocal, Fair, and Balanced Trade”, September 25th, 2025].

The certainties provided by the government's announcement were disturbed on the very same day by President Trump’s threat to increase tariffs on branded drugs to 100% starting October 1st, unless they are produced in the United States. The enforcement of the new tariff was suspended the following day and, in any case, the reaction of European industries was mild, owing to the US-EU agreements and the promised investments. Nearly all major pharmaceutical companies are present in the US and most have announced significant investments, including Swiss and British ones that are not part of the European Union [Handelsblatt, September 26th].

The effects of tariffs on the prices and availability of medicines in the American market, as well as on industry structure, are still uncertain. Under current provisions, it is not enough for European companies to have production sites in the US for their drugs to be exempt from the tariff; only drugs actually produced in the US will be exempt. Exemption can also be granted to products when the company has started to build a plant on American soil. Generic drugs and imported raw materials will not be subject to tariffs; the major producers of these are in India and China.

According to The New York Times, big corporations, which have the financial strength to invest in the US and the margins to negotiate significant price discounts with the administration, will in the end be largely spared. John Crowley, president of the Biotechnology Innovation Organization, which represents biotechnology companies and most of the large pharmaceutical firms, believes that the tariffs will hit small and mid-sized companies. Small brand-name drug manufacturers, who lack the billions of dollars to build new plants in the US and often rely on one or two niche products, will be penalised [“Trump’s Tariffs Would Spare Many Rich Drugmakers While Punishing Some Small Ones”, The New York Times, September 26th, 2025].

It is possible that one of the effects of Trump’s tariff policy will be a push towards industrial consolidation.

Between America and China

While the American market remains fundamental, Chinese innovative capacity exerts an ever-stronger attraction on Life Sciences multinationals. In the last five years, eleven of the largest Big Pharma companies have invested a total of $150 billion as part of agreements with Chinese companies [Nature, September 1st].

The case of the Anglo-Swedish company AstraZeneca serves as an example of the commitment of European biopharmaceutical companies to the world’s two main markets. The multinational, listed in London and Stockholm, with a turnover of $54 billion and about 94,000 employees in 2024, is the sixth largest pharmaceutical company worldwide. It is the result of the merger, which took place in 1999, between the Swedish company Astra and the UK’s Zeneca; the latter, as part of the break-up of the historic giant ICI (Imperial Chemical Industries), inherited its pharmaceutical activities in 1993.

At the end of July, the company announced its intention to invest $50 billion to boost pharmaceutical production and research over a period of five years. Chief Executive Pascal Soriot describes it as a historic investment, which justifies the ambition of earning $80 billion in turnover by 2030 [Financial Times, July 30th]. On November 12th last year, before the trade war broke out, the company had already announced the suspension of investments in the United Kingdom and an investment of $3.5 billion in production and R&D in the United States. A multi-billion-dollar investment — declared Soriot — that reflects the attractiveness of the business environment together with the quality of talent and innovation capabilities here in the United States [“AstraZeneca Invests $3.5 Billion in R&D and Manufacturing in the United States”, November 12th, 2024].

The company reports having seven sites in the US, covering production, marketing, and R&D, with around 18,000 employees, spread across twelve States. The US is AstraZeneca’s largest market, accounting for 42% of total revenue. The announced investments are intended for the construction of new production and R&D facilities and the expansion of existing ones, targeting a broad spectrum of pathologies, with particular focus on chronic and oncological conditions. For example, last May the company announced the opening of its new cell therapy production site in Maryland, where it has invested $300 million [Fierce Pharma, May 6th]. Investments announced at the end of July include the construction of a new plant in Virginia for the production of active pharmaceutical ingredients.

AstraZeneca is among the pharmaceutical multinationals that invested the most in China in 2025, signing strategic agreements with Chinese biotechnology companies for a potential value of over $10 billion.

In the current tariff dispute, it is not only — or even chiefly — goods that are at stake, but rather the export of capital.

Lotta Comunista, October 2025

Labels:

Popular posts in the last week

The EU Commission Plans for Rearmament and a Clean Industrial Deal

Internationalism No. 71, January 2025 Page 2 From the series European news Following the European elections which took place on June 6th - 9th, the leaders of the Member States met on June 27th at the European Council. Ursula von der Leyen was nominated as president of the next European Commission, after she was chosen as the European People’s Party’s (EPP) Spitzenkandidat (“leading candidate”). The agreement also included the election of former Portuguese Prime Minister Antonio Costa as president of the European Council, and the appointment of former Estonian Prime Minister Kaja Kallas as High Representative of the Union for Foreign Affairs and Security Policy. Subsequently, on July 18th, Parliament elected von der Leyen as president of the Commission by an absolute majority, with 401 votes out of 719 MEPs. On September 17th, von der Leyen presented her team of commissioners to the European Parliament and, two days later, the Council adopted this list of...
Read more

The Fourth Plenum of China's War Preparations

Internationalism No. 83, January 2026 Page 2 According to Nicolas Baverez of Le Figaro , China’s proposed Five-Year Plan for 2026-2030, accepted by the Fourth Plenum of the CCP Central Committee, marks China’s transition to a war economy . At the national level, the focus would not be on rebalancing demand, but on reducing dependencies in order to resist external pressures and international sanctions. War preparations, writes the French economist, are now fully integrated into China’s economic development strategy. In our view, it would be more accurate to speak of a rearmament economy , since no major power has yet moved towards the proportions of a full-scale war effort, i.e., military spending historically measured in tens of percentage points of GDP. Instead, the variations have so far been a few percentage points and fractions of a point. This does not mean that there is no rearmament process affecting the economy and society as a whol...
Read more

India’s Weaknesses in the Global Spotlight

Farmers’ protests around New Delhi have been going on for four months now. A controversial intervention by the Supreme Court has suspended the implementation of the new agticultural laws, but has raised questions about the dynamics between the judiciary and the executive, and has failed to unblock the negotiations between government and peasant organisations. The assault by Sikh farmers on the Red Fort during the Republic Day parade as India was displaying its military might to the outside world — the Chinese Global Times maliciously noted — paradoxically widened the protest in the huge state of Uttar Pradesh. The Modi government has been trying to revive India’s image with the 2021 Union Budget: it announced one hundred privatisations and approved the increase to 75% of the limit on direct foreign investment in insurance companies. For The Indian Express ( IEX ) this is a sign of the commitment to push ahead with reforms despite the backlash from rural India. Also for The Economi...
Read more

“Polish Moment” at Risk

Internationalism No. 78-79, August-September 2025 Page 3 From the series European news In July, the strategic triangle of London-Paris-Berlin was strengthened with the Northwood Declaration, in which the United Kingdom and France signalled the possibility of coordinating the use of their nuclear weapons through the creation of a “Nuclear Steering Group”, and with the Kensington Treaty, an Anglo-German defence pact. These agreements complement the Franco-British agreements of Lancaster House and the Franco-German Treaty of Aachen. Although Poland signed the Treaty of Nancy with France in May 2025, it was excluded from the recent “E3” consultations, in which only the United Kingdom, France, and Germany participated. Nevertheless, the establishment of the new government led by Donald Tusk, the Civic Platform (PO) leader, in the October 2023 elections, after eight years of antagonism with Brussels under the Law and Justice Party (PiS)-dominated government, ha...
Read more

The Defeat in Afghanistan — a Watershed in the Cycle of Atlantic Decline

In crises and wars there are events which leave their mark on history because of how they make a decisive impact on the power contention, or because of how, almost like a chemical precipitate, they suddenly make deep trends that have been at work for some time coalesce. This is the case of the defeat of the United States and NATO in Afghanistan, which is taking the shape of a real watershed in the cycle of Atlantic decline. For the moment, through various comments in the international press, it is possible to consider its consequences on three levels: America’s position as a power and the connection with its internal crisis; the repercussions on Atlantic relations and Europe’s dilemmas regarding its strategic autonomy; and the relationship between the Afghan crisis and power relations in Asia, especially as regards India’s role in the Indo-Pacific strategy. Repercussions in the United States Richard Haass is the president of the CFR, the Council on Foreign Relations; despite having ...
Read more

The Unstoppable Force: Capital’s Demand for Migrant Labour

Internationalism No. 78-79, August-September 2025 Page 16 “Before Giorgia Meloni became Italy’s prime minister, she pledged to cut immigration. Since she has been in government the number of non-EU work visas issued by Italy has increased”. This is how The Economist of April 26th summarises the schizophrenia of their politics; and this is not only true in Italy: “Net migration also surged in post-Brexit Britain”. The needs of the economic system do not coincide with the rhetoric of parliamentarism. And vice versa. Schizophrenia and imbalances in their politics Returning to Italy, the Bank of Italy has pointed out that by 2040, in just fifteen years, there will be a shortage of five million people of working age, which could lead to an estimated 11% contraction in GDP. This is why even Italy’s “sovereignist” government is preparing to widen the net of its Immigration Flow Decree. The latest update, approved on June 30th, provides for the entry of almost ...
Read more

The National Gamble of Poland

Internationalism No. 33, November 2021 Page 3 From the series European News In a lawsuit brought by Prime Minister Mateusz Morawiecki, the Constitutional Tribunal, which is composed of judges chosen by the government, ruled that fundamental parts of the EU Treaty are incompatible with the Constitution of the Republic of Poland. This ruling thus denies the primacy of European law over national law, undermining both the political assumption of continental integration and the supranational character of the EU . Vectors of Polish history We can shed light on this event if we consider the four field vectors that cross Poland: its traditional ethnic-religious nationalism, its marked Atlantic tropism, the objective attraction exerted by the European force field, and the looming threat of Russia. The general picture is global collisions: China’s irruption and the crisis in the world order have put pressure on Warsaw to define its st...
Read more

Political Battles of European Leninism

Internationalism No. 73, March 2025 Page 1 Thirty years after the death of Arrigo Cervetto , we are publishing here the concluding passages of the introduction to his Opere Scelte (“Selected Works”) for the series Biblioteca Giovani (“Publications for young people”), soon to be published in Italian. The 1944-45 partisan war in Italy. The political battle within libertarian communism. The Korean War, and the watchword of “neither Washington nor Moscow”. The layoffs at the Ilva and Ansaldo factories, the political battle and trade union defence in the struggles of post-war restructuring. From 1953 onwards, the crisis of Stalinism, the 1956 Suez crisis, the Hungarian uprising, the 1957 Theses and the challenge of theory and strategy vis-à-vis the tendencies of unitary imperialism. The political struggle within Azione Comunista (“Communist Action”) and the Movimento della Sinistra Comunista (“Movement of the Communist Left”). From the 1950s to the early 1970s, t...
Read more

India’s Lift-Off

Internationalism No. 84, February 2026 Page 13 From the series The world steel battle Just over fifteen years ago, in the article “La rincorsa siderurgica dell’India” [ India’s Steel Catch-Up , April 2010], we focused on the rise of the Indian steel industry. Today, it ranks among the world’s giants and second only to China, having overtaken the United States, Japan, and finally the EU-27 plus the United Kingdom. In the early months of 2025, the annual growth rate of Indian steel production was still above 10%, compared with stable figures not only for global production but also for Chinese output. Alongside the advance of the national steel industry, Indian families at the head of major steel groups are increasingly active internationally. In addition to the Mittal and Tata dynasties, Gupta’s Liberty Steel and the two branches of the Jindal family are now present on the global market. ...
Read more

Armed Negotiations between the Gulf and the Mediterranean

David Petraeus, Commander of the US forces in Iraq and the Gulf in 2007-2008, then director of the CIA in 2011-12, described the elimination of Iranian General Qasem Soleimani on January 3 rd in Baghdad as a defensive action , with which the Trump presidency restored a US deterrence , which was weakened by recent Iranian actions . This is a reference to the attacks conducted indirectly, unclaimed by Tehran, against the Saudi oil infrastructures on September 14 th 2019. In March 2008, when the forces under Petraeus’ command supported the Iraqi Army in the fight against local Shite militias, Soleimani sent a message to the American general: informing him that he was the person in charge for Iranian policies in Iraq, Syria, Lebanon and Gaza therefore the channel through which to define an agreement to resolve the various issues with Tehran. Petraeus holds the advisors of the Quds Force, the spearhead of the Pasdaran asymmetric operations, responsible for the killing of around 600 ...
Read more